Core Viewpoint - The report highlights the financial performance of Shandong Weigao Blood Purification Products Co., Ltd. for the first half of 2025, showing growth in revenue and profit metrics compared to the previous year [1]. Financial Performance - Total assets increased to CNY 8,116,417,542.53, representing a 16.11% increase from the previous year [1]. - Operating revenue for the period was CNY 1,764,680,364.12, an increase of 8.52% compared to CNY 1,626,059,280.30 in the same period last year [1]. - Total profit reached CNY 264,162,482.38, marking a 10.89% increase from CNY 238,227,294.47 [1]. - Net profit attributable to shareholders was CNY 214,612,844.34, up 9.64% from CNY 195,742,434.83 [1]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 65,823,050.56 (including tax), which accounts for 29.89% of the net profit attributable to shareholders [1]. Shareholder Information - The largest shareholder, Weigao Group Co., Ltd., holds 41.75% of the shares, followed by Shandong Weigao Medical Polymer Co., Ltd. with 23.90% [2]. - Other significant shareholders include Weihai Kaide Information Technology Center (Limited Partnership) with 9.69% [2]. Corporate Governance - The report indicates that the company has not identified any significant changes in its operational situation during the reporting period [5].
威高血净: 山东威高血液净化制品股份有限公司2025年半年度报告摘要